Print（PDF/129KB） Aug. 04, 2025 Corporate

Sumitomo Pharma Announces Organizational Realignments and Personnel Changes

Sumitomo Pharma Co., Ltd. (Head Office: Osaka, Japan; Representative Director, President and CEO: Toru Kimura) today announced the following organizational realignments and personnel changes, effective September 1, 2025.

1. Organizational Realignments (effective September 1, 2025)

Research and Development

1. 1. Part of the functions of Clinical Planning and Clinical Operation are integrated and reorganized to newly establish Translational Medicine and Early Development, Oncology Clinical Development, and CNS Clinical Development.
2. 2. Part of the functions of the Clinical Operation are transferred to R&D Management and Data Science.

2. Changes in Personnel (effective September 1, 2025)

Research and Development

Position as of September 1, 2025	Current position	Name
Senior Vice President, Deputy Head of Research and Development Division (Project Planning and Promotion, Translational Research)	Senior Vice President, Deputy Head of Research and Development Division (Project Planning and Promotion)	Taro Kato
Vice President, Head of Translational Medicine and Early Development Senior Director, Translational Research Group,Translational Medicine and Early Development	Vice President, Sumitomo Pharma America, Inc.	Taiji Ono
Vice President, Head of Oncology Clinical Development Senior Director, Oncology Clinical Research & MA Group, Oncology Clinical Development	Senior Director, Oncology Clinical Research Group, Clinical Planning	Tomohiro Tada
Vice President, Head of CNS Clinical Development	Senior Director, MA Group II, Medical Affairs	Masaya Mori
Vice President, Head of Medical Affairs	Vice President, Head of Clinical Operation	Hideaki Takahashi